Investigating mutations in a gene related to kidney cancer and its impact on blood vessel growth
Official title: PBRM1 bromodomain missense mutations in ccRCC vascular signaling
Funded at Medical College of Wisconsin · NIH-11101360 · Data updated 2026-11-12
This study is looking at how certain changes in a gene called PBRM1 affect kidney cancer and how well it responds to treatments that stop blood vessels from growing, with the goal of finding better therapies that work for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $51,628 |
| NIH project number | 5F30CA278386-03 |
| Project ID | NIH-11101360 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma, particularly those with specific mutations in the PBRM1 gene.
✕Less likely to help
Patients with other types of kidney cancer or those without PBRM1 mutations may not benefit from this research.
What this research studies
This research focuses on clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer that often presents with advanced disease. The study aims to understand how specific mutations in the PBRM1 gene affect the cancer's vascular signaling and response to anti-angiogenic therapies, which are treatments that inhibit blood vessel growth. By analyzing these mutations, the research seeks to identify potential targeted therapies that could improve patient outcomes and reduce side effects associated with current treatments. Patients may be involved in providing samples or data to help elucidate the role of these mutations in their cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with clear cell renal cell carcinoma.
How similar studies have gone: Previous studies have shown promising results with anti-angiogenic therapies in ccRCC, but this specific focus on PBRM1 missense mutations is relatively novel.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Bursch, Karina Lynn — Medical College of Wisconsin
- Study coordinator: Bursch, Karina Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.